Synergy Pharmaceuticals (FRA:S90) Cash-to-Debt : 0.38 (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Synergy Pharmaceuticals's cash to debt ratio for the quarter that ended in Sep. 2018 was 0.38.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Synergy Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2018.

The historical rank and industry rank for Synergy Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

FRA:S90' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: No Debt Max: No Debt
Current: 0.38

During the past 12 years, Synergy Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.13. And the median was No Debt.

FRA:S90's Cash-to-Debt is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.95 vs FRA:S90: 0.38

Synergy Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Synergy Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Synergy Pharmaceuticals Cash-to-Debt Chart

Synergy Pharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.05

0.74

3.64

1.18

Synergy Pharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Cash-to-Debt	Get a 7-Day Free Trial															1.04	1.18	0.85	0.52	0.38

Competitive Comparison of Synergy Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synergy Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's Cash-to-Debt falls into.

Synergy Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Synergy Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2017 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	115.753	/	(0	+	97.988)
	=	1.18

Synergy Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Sep. 2018 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	39.119	/	(102.474	+	0)
	=	0.38

Synergy Pharmaceuticals (FRA:S90) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Synergy Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Synergy Pharmaceuticals (FRA:S90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170

Website

http://www.synergypharma.com

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines